"ID";"Original Title";"Title";"Summary";"Contact";"Citation";"URL Scientific Article";"More References";"Keywords";"Field of Research";"Method/Model";"Year of Publication";"Month of Publication";"Date of Editing"; "1684";"The drug-induced phenotypic landscape of colorectal cancer organoids";"Drug-induced phenotypic landscape of colorectal cancer organoids";"Here, a large-scale image-based phenotyping study of patient-derived cancer organoids was reported to understand underlying factors governing organoid morphology. Colorectal cancer organoids from 11 patients were treated with more than 500 experimental and clinically used small molecules at different concentrations. The morphological heterogeneity of patient-derived organoids and their response to compound perturbations from more than 3,700,000 confocal microscopy images were mapped. The authors found that the resulting landscape of organoid phenotypes was mainly driven by differences in organoid size, viability and cystic vs. solid organoid architecture. Using multi-omics factor analysis for integrating organoid morphology, size, gene expression, somatic mutations and drug activity, biological programs underlying these phenotypes and small molecules that modulate them were identified.";"Matthias P. Ebert, University Medical Center Mannheim, Mannheim, Germany, Michael Boutros, German Cancer Research Center (DKFZ), Heidelberg, Germany";"Johannes Betge et al. Nature Communications 2022";"https://www.nature.com/articles/s41467-022-30722-9";"";"personalised medicine, tumor organoids, cancer therapy, high content screening";"Gastroenterology, Hepatology, Drug development and testing, Oncology";"Human studies, Epidemiology, Organoids, Spheroids, OMICs, Big data";"2022";"06";"2022-12-15 08:45:55";